Home > Insider Trading > Filing (0000950170-24-098859)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
873303	Sarepta Therapeutics Inc.	SRPT	Pharmaceutical Preparations (2834)	930797222

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1932527	Andrew Michael Chambers	215 First Street Suite 415 Cambridge MA 02142		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-08-16	13,106	$133.07	260,102	No	4	P	Indirect	By Revocable Trust
Common Stock	Acquisiton	2024-08-16	18,284	$134.06	278,386	No	4	P	Indirect	By Revocable Trust
Common Stock	Acquisiton	2024-08-16	5,648	$134.66	284,034	No	4	P	Indirect	By Revocable Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Revocable Trust
No	4	P	Indirect	By Revocable Trust
No	4	P	Indirect	By Revocable Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,277	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $132.46 to $133.46, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $133.47 to $134.47, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $134.48 to $134.82, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.